Literature DB >> 23796088

Phase II study of percutaneous transesophageal gastrotubing for patients with malignant gastrointestinal obstruction; JIVROSG-0205.

Takeshi Aramaki1, Yasuaki Arai, Yoshitaka Inaba, Yozo Sato, Hiroya Saito, Miyuki Sone, Yoshito Takeuchi.   

Abstract

PURPOSE: This multicenter, prospective study was conducted to evaluate the efficacy of percutaneous transesophageal gastrotubing (PTEG) as an esophagostomy procedure for bowel decompression in patients with malignant bowel obstruction.
MATERIALS AND METHODS: The study subjects were patients with malignant bowel obstruction treated with a nasogastric tube (NGT). After receiving PTEG, efficacy evaluations were conducted, with NGT designated as the control state. The procedure was considered effective only when discomfort in the nasopharynx was improved for at least 2 weeks. Safety was evaluated by using National Cancer Institute Common Toxicity Criteria, version 2.0. PTEG was performed by using a PTEG kit.
RESULTS: From February 2003 to December 2005, 33 patients were enrolled. The technical success rate was 100%, and the procedure was considered effective in 30 of 33 cases. The three cases in which the procedure was ineffective could not be evaluated as a result of deterioration of general status or early death. The one recorded complication was a tracheoesophageal fistula that caused grade 2 aspiration pneumonia.
CONCLUSIONS: PTEG is an effective technique to relieve discomfort in the nasopharynx caused by NGT in patients with terminal malignant tumors. PTEG should be considered an efficacious method for bowel decompression in patients who are ineligible for surgical procedures, percutaneous gastrostomy, or percutaneous enterostomy.
Copyright © 2013 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23796088     DOI: 10.1016/j.jvir.2013.04.005

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  3 in total

1.  Safety and efficacy of percutaneous transabdominal and transesophageal decompression gastric catheters for palliation of malignant bowel obstruction.

Authors:  Robert J Litwin; Alda L Tam; Rahul A Sheth; Steven M Yevich; Johanna L Chan; Amir A Jazaeri; Josiah K Halm; Sanjay Gupta; Steven Y Huang
Journal:  Abdom Radiol (NY)       Date:  2021-05-17

2.  Percutaneous transesophageal gastro-tubing (PTEG) as an alternative long-term tube feeding procedure when gastrostomy is not feasible.

Authors:  Ezekiel Wong Toh Yoon; Kazuki Nishihara
Journal:  Therap Adv Gastroenterol       Date:  2017-09-20       Impact factor: 4.409

3.  MASCC multidisciplinary evidence-based recommendations for the management of malignant bowel obstruction in advanced cancer.

Authors:  Ainhoa Madariaga; Jenny Lau; Arunangshu Ghoshal; Tomasz Dzierżanowski; Philip Larkin; Jacek Sobocki; Andrew Dickman; Kate Furness; Rouhi Fazelzad; Gregory B Crawford; Stephanie Lheureux
Journal:  Support Care Cancer       Date:  2022-03-10       Impact factor: 3.359

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.